


Journal Pre-proof

Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis

Philipp Schreiner, MD, Silas Meissgeier, Ekaterina Safroneeva, PhD, Thomas Greuter, MD, Gerhard Rogler, MD, Alain Schoepfer, MD, Dagmar Simon, MD, Hans-Uwe Simon, MD, PhD, Luc Biedermann, MD, Alex Straumann, MD



PII: S1542-3565(19)31397-7
DOI: <https://doi.org/10.1016/j.cgh.2019.11.057>
Reference: YJCGH 56897

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 27 November 2019

Please cite this article as: Schreiner P, Meissgeier S, Safroneeva E, Greuter T, Rogler G, Schoepfer A, Simon D, Simon H-U, Biedermann L, Straumann A, Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2019.11.057>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 by the AGA Institute

Manuscript Number: CGH 19-02038

Title: Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis

Short title: Eosinophilic esophagitis and pregnancy

Philipp Schreiner MD^{1*}, Silas Meissgeier^{1*}, Ekaterina Safroneeva PhD², Thomas Greuter MD¹, Gerhard Rogler MD¹, Alain Schoepfer MD³, Dagmar Simon MD⁴, Hans-Uwe Simon MD, PhD^{5,6}, Luc Biedermann MD¹, Alex Straumann MD^{1,7}

*equally contributed

1 Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

2 Institute of Social and Preventive Medicine, University of Bern, Switzerland

3 Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

4 Department of Dermatology, Bern University Hospital, Inselspital, University of Bern, Switzerland

5 Institute of Pharmacology, University of Bern, 3010 Bern, Switzerland

6 Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia

7 Swiss EoE Clinic Olten, Switzerland

Abbreviations:

EoE: Eosinophilic esophagitis

Eos/hpf: Eosinophils per high power field

PPI: Proton pump inhibitors

Th1/2: T-helper cell ½

Corresponding author:

27 Philipp Schreiner, Division of Gastroenterology and Hepatology, University Hospital Zurich,
28 Raemistrasse 100, 8091 Zurich, Switzerland.
29 E-mail: Philipp.schreiner@usz.ch

30 **Guarantor of the article:** Philipp Schreiner

31 **Specific author contributions:** Philipp Schreiner conception and design of the study,
32 drafting the article, approved the final version. Silas Meissgeier conception and design of the
33 study, drafting the article, approved the final version. Thomas Greuter design of the study,
34 critical revision and approved the final version. Gerhard Rogler design of the study, critical
35 revision and approved the final version. Alain Schoepfer design of the study, critical revision
36 and approved the final version. Ekaterina Safroneeva design of the study, critical revision and
37 approved the final version. Dagmar Simon design of the study, critical revision and approved
38 the final version. Hans-Uwe Simon design of the study, critical revision and approved the
39 final version. Luc Biedermann design of the study, critical revision and approved the final
40 version. Alex Straumann concept and design of the study, critical revision and approved the
41 final version.

42 **Financial support:** No financial support and no conflict of interest

43

Abstract:

Background & Aims: Eosinophilic esophagitis (EoE) most often affects young patients of reproductive age, yet little is known about its effects during pregnancy. We examined the course of EoE during pregnancy, outcomes of pregnancies, and patient concerns related to pregnancy and EoE.

Methods: We sent a survey that queried demographic and disease-specific characteristics as well as pregnancy-related topics to all 151 female patients treated at 2 EoE centers in Switzerland. We analyzed cross-sectional survey data.

Results: Of 72 patients that returned the survey, we identified 20 patients that had at least 1 pregnancy and analyzed the data on 34 pregnancies. During pregnancy, improvement of dysphagia was reported in 56% (19/34) of all pregnancies, whereas deterioration was reported in 20% (7/34) of all pregnancies. After delivery, dysphagia returned to the pre-pregnancy level in 68% (13/19) of all pregnancies for patients with improvement of dysphagia and 57% (4/7) of all pregnancies for patients with deterioration of dysphagia during pregnancy. Esophagogastroduodenoscopy during pregnancy was required in less than 10% (3/34) of all pregnancies. Pregnancy-related complications occurred in 12% of pregnancies (4/34). The leading patient-reported concerns were fear of heritability (40% of patients, 8/20) and concerns of that use of medication would harm the fetus (30% of patients, 6/20).

Conclusions: Pregnancy affects the course of EoE, with improvement of symptoms reported in most patients. Dysphagia returned to the pre-pregnancy level following delivery. EoE has likely no negative effects on outcomes of pregnancies.

KEY WORDS: esophagus, prenatal, neonate, chronic inflammatory disease

Journal Pre-proof

Introduction

Eosinophilic Esophagitis (EoE) is a chronic immune-mediated disease of the esophagus characterized clinically by symptoms of esophageal dysfunction and histologically by an eosinophil predominant inflammation.¹ Because the peak incidence of this disease is among those between 20 and 30 years of age, female patients are often diagnosed and live with this condition during their reproductive age.¹

Since EoE has a Th2-type inflammatory pattern² and may be considered as “asthma or atopic dermatitis of the esophagus”, its disease course during pregnancy might follow the one-third rule: disease ameliorates in a third of patients, disease deteriorates in a third of patients, and disease remain unchanged in a third of patients as in asthma³; or that the disease might deteriorate in the majority of patients as in atopic dermatitis.⁴ It is generally considered that these allergic and autoimmune diseases course alterations during pregnancy occur as a result of down-regulation of Th1 cells and the up-regulation of Th2 cells,^{5, 6} as high concentrations of Th1- and Th17-type cytokines may have deleterious effects on outcome of pregnancy.^{7, 8} In general, patients with chronic diseases may have unique challenges and concerns during pregnancy.⁹ From EoE patients’ perspective, it is important to know whether this condition has any consequences for a planned pregnancy.

To date, the data on pregnancy in EoE are extremely limited, with a single case series of four pregnant women in EoE published by Burk *et al.*¹⁰ The aim of this study was three-fold: to investigate the clinical course of EoE during pregnancy, to analyze the outcome of the pregnancies in patients with EoE, and to explore the disease-specific concerns female EoE patients might have had before pregnancies.

Methods

We conducted a cross-sectional questionnaire-based study in all female EoE patients treated at EoE Clinics in Olten and Zurich, Switzerland. Diagnosis of EoE was established based on the following criteria: clinically, based on presence of symptoms of esophageal dysfunction and histologically, based on esophageal peak eosinophilia of ≥ 15 eosinophils per high-power field (eos/hpf) in at least one biopsy specimen of the esophagus.¹¹ Other conditions leading to esophageal eosinophilia were excluded. We developed a German language-based survey that queries the number of pregnancies, pregnancy complications (premature birth, miscarriage, gestational diabetes, high blood pressure, or other complications), mode of delivery, EoE-specific pregnancy-related concerns (fear of heritability, fear of harming the unborn due to medication use, fear of EoE negatively impacting the course of pregnancy, fear of EoE deterioration, or other concerns), the presence of EoE symptoms including dysphagia during pregnancy and following delivery as well as change in EoE symptom severity (improvement or deterioration) in percent (10-30%, 31-50%, 51-70%, 71-100%) following the delivery compared to symptom severity during pregnancy, any EoE-related complication during pregnancy, the need of esophagogastroduodenoscopy during pregnancy, and the medication use and dose during pregnancy. Demographic and disease-specific data, such as age at the time of study enrollment, age at first manifestation and diagnosis of EoE, concurrent allergic diseases, and history of bolus impaction were also collected. The survey was sent and returned by post.

All statistical analyses were performed using the GraphPad Prism 5.0 (GraphPad Software, Inc., Sand Diego, CA). Quantitative data distribution was analyzed using Normal-QQ-Plots. Results of quantitative data are presented either as median plus interquartile ranges (for data with non-Gaussian distribution) or mean \pm SD and range (for normally distributed data). Categorical data were summarized as the percentage of the group total. For quantitative data,

118 differences in distribution between two groups were evaluated using either the Wilcoxon-
119 Mann-Whitney rank test (for data with non-Gaussian distribution) or the Student's t-test (for
120 normally-distributed data). For categorical outcomes, differences in observed frequencies
121 between groups were compared using the chi-squared test, or using the exact Fisher test for
122 groups with a small number of observations ($n < 20$).

123 The study was approved by the local ethics committee (No. EKNZ 2015-388).

RESULTS

One hundred and fifty one female patients are treated in EoE clinics in Olten and Zurich, Switzerland. These patients were invited to participate in this study and were send paper-based survey. Seventy-two patients (48%) returned the survey and were included in this study. Of 72 enrolled patients, 20 patients had at least one pregnancy after EoE diagnosis. Six patients (30%) had one pregnancy, whereas 14 patients (70%) had two pregnancies (total of 34 pregnancies) (Figure 1). One patient was pregnant at the time of the survey completion. The demographic and disease-specific characteristics are shown in Table 1.

The course of the dysphagia during pregnancy and after delivery is shown in Figure 2. Most patients experienced improvement in dysphagia during their pregnancies (56%), a quarter of patients observed no change in dysphagia, and a fifth experienced worsening of dysphagia. In patients reporting an improvement of dysphagia, more than half experienced an improvement by 71-100%, whereas in patients with a deterioration, the majority had only a deterioration of less than 30%.

After delivery, the severity of dysphagia returned to the pre-pregnancy state in the majority of patients. The median duration of improvement or deterioration in dysphagia severity during pregnancy was 3.0 months (IQR 0) or 6.0 months (IQR 1 month), respectively. After pregnancy, an improvement in dysphagia severity occurred after a median of 3.1 month (IQR 3.8 month), whilst a deterioration in dysphagia severity occurred after a median of 2.0 month (IQR 5.8 month). During pregnancy, three patients (9%) experienced EoE-related complications requiring esophagogastroduodenoscopy: bolus impactions (n=2), and herpes simplex esophagitis (n=1).

Pregnancy-specific characteristics are shown in Table 2. Complications occurred in four (12%) of the pregnancies including one miscarriage. At the time point of data analysis, one patient was still pregnant.

In 14 pregnancies (41%), patients did not take any EoE-specific medications. Of the remaining pregnancies, swallowed topical corticosteroids (STC), proton-pump inhibitors (PPI), and elimination diet were used in 13 (39%), nine (26%), and two pregnancies (6%), respectively. The rate of EoE-related complications requiring esophagogastroduodenoscopy in patients treated with EoE-specific modalities (2/20, 10%) and that in patients that did not undergo treatment (1/14, 7.1%) did not appear to differ ($P = ns$). Furthermore, the rate of pregnancy-related complications in patients (who finished their pregnancy) treated with EoE-specific therapies (1/20, 5.0%) and that in patients without treatment (3/13, 23.1%) did not appear to differ ($P = ns$).

The major concerns reported by patients with prior pregnancy were fear of child inheriting EoE (40%), and fear of harming the child due to EoE medication use (30%). Only a minority of patients were concerned about a negative effect of pregnancy on EoE course or vice versa. Half of the patients (50%) reported no concerns at all (Table 2).

DISCUSSION

Eosinophilic esophagitis (EoE) has an increasing prevalence and frequently affects individuals of child-bearing age. Whilst the study on contribution of genetic and environmental factors to EoE heritability have recently been carried out,¹² the studies on impact of a pregnancy on esophageal inflammation and clinical disease course as well as outcome of pregnancies in EoE patients are scarce. In this survey-based study, we describe the case series of 20 EoE patients that experienced 34 pregnancies. Our main findings are as follows: 1) more than half of the EoE patients experienced symptom improvement during pregnancy; 2) the rate of pregnancy-related complications was low; and 3) major concerns reported by patients were fear of child inheriting EoE and harming the unborn child due to EoE medication use.

Given that during pregnancy clinical worsening of several autoimmune diseases, such as asthma and atopic dermatitis, was demonstrated in several studies^{3, 4}, we learned with interest that more than half of the patients (56%) reported a marked improvement in their dysphagia, whereas only a minority (20%) of patients experienced deterioration of dysphagia severity. Our data pave way for prospective studies closely examining the alterations in EoE course during pregnancy as well as mechanistic work aimed to explore whether the pregnancy results in changes in levels of expression of various cytokines compared to pre/post-pregnancy state.

Chronic inflammation might have a negative impact on the outcome of pregnancies, either as a consequence of the disease activity itself or due to side effects of the treatment. In EoE, the risks of an uncontrolled disease activity as well as side effects of corticosteroids and potential nutritional deficits in those adhering to dietary regimens are all grounds for concern for healthcare professionals taking care of EoE patients. This was not the major concern for our EoE patients, as only one of the twenty patients feared that EoE might negatively impact the course of pregnancy. Our data show that the course of the pregnancies and deliveries were uneventful in almost 90% of all cases. A miscarriage occurred in one patient (3%). Since the

miscarriage rate in high-income countries is approximately 10% in young women, it appears that the prevalence of miscarriage in EoE patients is similar to that observed in the general population.¹³ In addition, the incidence of premature birth (3%) and the rate of placental abruption (3%) in our study population is similar to that in other northern European countries (premature birth is observed in approximately 5% of patients, whilst placental abruption is observed in approximately 1% of patients).^{14,15} In summary, we did not document a negative impact of the underlying EoE on the course and the outcome of the pregnancies.

Almost one third of patients had concerns that their medication could have a negative impact on the outcome of the pregnancy. The only approved medication for treatment of EoE are swallowed topical corticosteroids (STC), which have a favorable safety profile and represent the first-line treatment in non-pregnant patients.^{16,17,18} Topically-acting corticosteroids can be safely administered during pregnancy in patients with skin diseases and asthma.^{19,20} However, one must keep in mind that STC are metabolized differently depending on the mode of application. In our study, three pregnancy-related complications occurred in patients that did not undergo any treatment (3/13; 21.3%), and one complication (1/20; 5.0%) occurred in the group undergoing treatment. The one complication in a patient treated with STC was a herpes esophagitis. However, that was supposed to be unrelated to the medication and more a surrogate marker for an uncontrolled EoE. In summary, the rate of pregnancy-related complications was not higher in patients adhering an anti-inflammatory treatment with STC during pregnancy when compared to that in patients taking no medications for EoE management.

Mode of delivery is an important topic for expectant mothers regardless of whether they have a chronic disease or not. In Switzerland, caesarean section rate of 33% is one of the highest worldwide.¹⁴ Our analysis demonstrated that more than 40% of our EoE patients had a caesarean section. As such, the rate of caesarean section in our population is consistent with nation-wide rates.

Parents affected by chronic diseases often fear of transmitting the disease to their children. Our data show that almost half of the EoE patients were concerned that the offspring might inherit the disease. This fear is justified, as the risk for first-degree relatives to be affected with EoE is about 2.3%.¹² However, the environmental exposures increase the rate of EoE development to a much greater extent than genetic background.¹² Furthermore, the risk for transmitting EoE from father to the offspring is at least twice as likely as that from mother to the offspring. Therefore, we have no reasons to discourage female EoE patients from having children based on the increased risk of disease inheritance alone.

Our study has several limitations. Relatively small number of patients was examined. However, since the prevalence of EoE is three-fold lower in female than in male patients¹, it is difficult to study female patients that are of childbearing age and experienced pregnancy. Despite the low number, our study represents the largest number of pregnant EoE patients ever examined. Given the retrospective nature of the study, symptoms were assessed using a non-validated instrument. We did not collect the age when the women experienced pregnancy. However, the mean age in our population was not much higher than the mean age of having children in average population in Switzerland (32 years). In addition, given that only three patients underwent esophagogastroduodenoscopy for emergency reasons, we could not examine the relationship between symptom severity and biologic findings. Nevertheless, given the clinical need and almost complete absence of literature on course of pregnancy in patients with EoE, these data might be useful for management of these patients.

Based on our analysis and on practical experience, we provide the following four clinical suggestions: 1.) Female EoE patients considering pregnancy should be informed that to date no increased maternal and fetal risk was observed in pregnant EoE patients on and off EoE-specific medication; 2.) In patients having inactive disease at the beginning of a pregnancy, a cessation of the treatment may be considered, provided that the patients undergo

regular monitoring of EoE during pregnancy; 3.) In patients with active disease at the beginning of the pregnancy the treatment should be continued and 4). After delivery, patients having had an improvement in symptoms during pregnancy must be advised to pay attention to a worsening of symptoms.

In conclusion, our analysis indicates that clinical course of EoE appears to be favorable in pregnancy. Use of EoE-specific medications during pregnancy appears to be safe, as we could not detect a higher rate of pregnancy-related complications in patients having an EoE-specific therapy.

ACKNOWLEDGEMENTS

The authors would like to thank all the patients for their willingness to participate in this study.

FUNDING AND CONFLICT OF INTEREST

There is no conflict of interest for the work under consideration for publication.

REFERENCES

1. Arias A, Perez-Martinez I, Tenias JM, et al. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. *Aliment Pharmacol Ther.* 2016;43(1):3-15.
2. Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. *J Allergy Clin Immunol.* 2001;108(6):954-61.
3. Gluck JC, Gluck PA. The effect of pregnancy on the course of asthma. *Immunol Allergy Clin North Am.* 2006;26(1):63-80.
4. Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. *Br J Dermatol.* 1991;125(1):59-61.
5. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. *J Reprod Immunol.* 1996;31(1-2):81-95.
6. Reinhard G, Noll A, Schlebusch H, et al. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. *Biochem Biophys Res Commun.* 1998;245(3):933-8.
7. Raghupathy R, Makhseed M, Azizieh F, et al. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. *Hum Reprod.* 2000;15(3):713-8.

8. Wegmann TG, Lin H, Guilbert L, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? *Immunol Today*. 1993;14(7):353-6.
9. Tyler-Viola LA, Lopez RP. Pregnancy with chronic illness. *J Obstet Gynecol Neonatal Nurs*. 2014;43(1):25-37.
10. Burk CM, Long MD, Dellon ES. Management of Eosinophilic Esophagitis During Pregnancy. *Dig Dis Sci*. 2016;61(7):1819-25.
11. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011;128(1):3-20 e6; quiz 1-2.
12. Alexander ES, Martin LJ, Collins MH, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. *J Allergy Clin Immunol*. 2014;134(5):1084-92 e1.
13. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. *BMJ*. 2000;320(7251):1708-12.
14. Euro-Peristat Project. European Perinatal Health Report. Core indicators of the health and care of pregnant women and babies in Europe in 2015. November 2018. Available <http://www.europeristat.com>.
15. Tikkanen M. Placental abruption: epidemiology, risk factors and consequences. *Acta Obstet Gynecol Scand*. 2011;90(2):140-9.
16. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. *Gastroenterology*. 2012;143(2):321-4 e1.
17. Dellon ES, Woosley JT, Arrington A, et al. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. *Gastroenterology*. 2019;157(1):65-73 e5.
18. Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. *Aliment Pharmacol Ther*. 2015;41(9):797-806.
19. Chi CC, Wang SH, Kirtschig G. Safety of Topical Corticosteroids in Pregnancy. *JAMA Dermatol*. 2016;152(8):934-5.
20. Schatz M, Zeiger RS, Harden K, et al. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol*. 1997;100(3):301-6.

Legends:

Figure 1: Flow diagram.

Figure 2: Course of dysphagia during and after pregnancy.

Table 1: Demographic and disease-specific characteristics of the study population.

Table 2: Pregnancy-specific characteristics in patients with EoE.

Table 1

	Patients with pregnancy during EoE (n=20)	Patients without pregnancy post EoE diagnosis (n = 52)
Age, y, mean +- SD	39.2 +- 8.7	49.0 +-14.1
Age at first manifestation, y, mean +- SD	18.8 +- 7.1	31.3 +- 16.1
Age at diagnosis, y, mean +- SD	28.2 +- 8.4	39.6 +- 12.9
Diagnostic delay, y, mean +- SD	9.4 +- 9.4	10.1 +- 10.4
Concurrent allergic diseases, n (%)	14 (70)	37 (71)
Bolus impaction in past, n (%)	8 (40)	17 (33)
Desire to have children, n (%)	19 (95)	12 (23)
Number of pregnancies, n (%)		
1	6 (30)	4 *
2	14 (70)	0

Demographic and disease-specific characteristics of the study population


* Pregnancy before EoE diagnosis

Table 2


Number of Patients having Concerns regarding Pregnancy (%) (duplicates counted)	
None, n (%)	10/20 (50)
Heritability, n (%)	8/20 (40)
Fear of harming the child due to medication, n (%)	6/20 (30)
Fear of EoE negatively impacting the course of pregnancy, n (%)	1/20 (5)
Fear of EoE deterioration, n (%)	1/20 (5)
Number of Patients having Contact with Medical-Persons during Pregnancy because of EoE (%)	
Gastroenterologist	5/20 (25)
Gynecologist	3/20 (15)
None	12/20 (60)
Number of Pregnancies requiring Treatment for EoE during Pregnancy (%) (duplicates counted)	
None	14/34 (41)
Steroids	13/34 (39)
PPI	9/34 (26)
Elimination Diet	2/34 (6)
Number of Pregnancy-Complication (%)	
Total	4/33 (12)
Miscarriage	1/33 (3)
Premature Birth	1/33 (3)
Placental Abruption	1/33 (3)
Unknown	1/33 (3)
Mode of delivery (%)	
Vaginal delivery	19/33 (58%)
Caesarean section	14/33 (42%)

Pregnancy-specific characteristics in patients with EoE

Figure 1



Flow diagram



What you need to know

Need to Know

Background: Eosinophilic esophagitis (EoE) most often affects young patients of reproductive age, yet little is known about its effects during pregnancy.

Findings: Pregnancy affects the course of EoE, with improvement of symptoms reported in most patients. Dysphagia returned to the pre-pregnancy level following delivery.

Implications for patient care: EoE has likely no negative effects on outcomes of pregnancies.